

PerCP/Cy5.5 anti-mouse CD197 (CCR7)

Catalog # / Size: 1200575 / 25 µg
1200580 / 100 µg

Clone: 4B12

Isotype: Rat IgG2a, κ


Immunogen: Mouse CCR7 transfected RBL-2H3 cells

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2



C57BL/6 mouse splenocytes stained with CD3 (17A2) FITC and 4B12 PerCP/Cy5.5

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 microg per 10^6 cells in 100 microL staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes: The 4B12 antibody does not inhibit binding of ligand to receptor. Additional reported applications (for the relevant formats) include: immunoprecipitation. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302) is recommended prior to immunofluorescent staining.

Staining with clone 4B12 is recommended at 37°C ([see supplemental data of PE staining at differing temperatures](#)).

- Application References:**
- Ohl L, *et al.* 2004. *Immunity* 21:279.
 - Ritter U, *et al.* 2004. *J. Leukocyte Biol.* 76:472.
 - Lan YY, *et al.* 2005. *Am. J. Transplant.* 5:2649. (FC)
 - Lee JH, *et al.* 2007. *J. Immunol.* 178:301. (FC) [PubMed](#)
 - Kurooka M and Kaneda Y. 2007. *Cancer Res.* 67:227. (FC) [PubMed](#)
 - Thompson BD. 2007. *J. Biol. Chem.* 282:9547. (FC)
 - Sakai N, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:14098. (FC)
 - Turnquist HR, *et al.* 2007. *J. Immunol.* 178:7018. (FC)
 - Hwang IY, *et al.* 2007. *J. Immunol.* 179:439. (FC) [PubMed](#)
 - Kang SG, *et al.* 2007. *J. Immunol.* 179:3724.
 - Mao A *et al.* 2005. *J. Immunol.* 175:5146. [PubMed](#)
 - Allende ML, *et al.* 2008. *FASEB J.* 22:307. [PubMed](#)
 - Kang SG, *et al.* 2007. *J. Immunol.* 179:3724. [PubMed](#)
 - Chen H, *et al.* 2005. *J. Immunol.* 175:591. [PubMed](#)
 - Florido M, *et al.* 2009. *Immunobiology.* 214:643. [PubMed](#)

16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
18. Havenith SH, *et al.* 2014. *Int Immunol.* 26:183. [PubMed](#)
19. Goode D, *et al.* 2014. *PLoS Pathog.* 10:1004567. [PubMed](#)
-

Description: CD197 is also known as C-C chemokine receptor 7 (CCR7) or EBI-1. CCR7 is a G-coupled rhodopsin-like member of the GPCR superfamily with a predicted molecular weight of 43 kD that is expressed on hematopoietic stem cells, most naive T cells, some memory T cells, B subset, and mature dendritic cells. CCR7 is a receptor for the chemokines CCL19 (MIP3 β) and SLC (6CKine, Exodus-2, TCA-4, CCL21) that plays a role in thymocytes development, T cell adhesion at intestinal sites, the homeostatic recirculation of memory T cells, and chemotaxis.

Antigen
References:

1. Schweickart VL, *et al.* 1994. *Genomics* 23:643.
2. Yoshida R, *et al.* 1998. *J. Biol. Chem.* 273:7118.
3. Campbell JJ, *et al.* 1998. *J. Cell Biol.* 141:1053.
4. Willimann K, *et al.*